T1	Participants 222 281	patients with squamous cell carcinoma of the head and neck.
T2	Participants 400 531	Eighty-three patients with advanced disease were entered into the first study (43/chemotherapy; 40/control), and 60 into the second
T3	Participants 563 626	Patient randomization was stratified by stage (III/IV) and site
